Ethical statement:
All the participants were fully informed of the purpose of our experiment and signed the informed consent form. This research was approved by the ethics committee of Longyan First Affiliated Hospital of Fujian Medical University (Approval number. LYREC2023-k007-01). All procedures were performed in accordance with relevant guidelines, regulations, and the Declaration of Helsinki.
Participant Recruitment, Eligibility Criteria, and Sample Collection
A total of 211 individuals diagnosed with AR and 180 healthy participants (non-AR) were recruited from the otolaryngology outpatient department of Longyan First Affiliated Hospital of Fujian Medical University between January 2023 and May 2025. The diagnosis criteria for AR were adopted from the Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis17. Patients were required to exhibit no fewer than two clinical symptoms of AR, including nasal itching, sneezing, nasal congestion, or runny nose. In addition, nasal mucosal examination was required to demonstrate pallor and edema, and either the Skin Prick Test (SPT) result or the serum IgE test result had to be positive. The SPT was performed by dedicated staff in the outpatient allergen testing room to guarantee the accuracy and consistent results. All patients with AR underwent the Rhino conjunctivitis Quality of Life Questionnaire (RQLQ) and Total Nasal Symptom Score (TNSS) assessments with assistance from medical staff, and the scores were recorded for subsequent analysis.
Healthy volunteers undergoing routine physical examinations at the hospital were recruited as the non-AR group. Eligible participants had no personal or family history of AR, no history of asthma or other allergic diseases, no chronic sinusitis or other inflammatory diseases of the nasal cavity, and no respiratory tract infection within the previous month. In addition, individuals with a history of serious cardiac, hepatic, pulmonary, or renal diseases, or any malignant tumors, were excluded from the study.
The peripheral venous blood samples of the two groups of volunteers were collected. A portion of the anticoagulated venous blood was used for DNA extraction and for extracting plasma RNA. Another portion of the venous blood was separated to obtain serum, which was used for the detection of serum-related factors (immunoglobulin E (IgE), interleukin-4 (IL-4), IL-6, and IL-10).
DNA Extraction:
200 µL of peripheral venous blood samples were extracted for DNA using the whole blood genomic DNA extraction kit (Refer to Table of Materials). The blood samples were collected into lithium heparin anticoagulation tubes and then aliquoted and frozen at -20 °C for storage. The specific operation procedures should strictly follow the instructions of the kit. Finally, 100 µL of elution buffer was used to elute the DNA. The purity of the extracted DNA sample was determined by the nucleic acid/protein analyzer (Spectrophotometer) (the OD₂₆₀/OD₂₈₀ ratio was between 1.8 and 2.0). The DNA samples after the detection were stored at -20 °C for future use in the subsequent genotyping experiments.
Genotype Detection
The TaqMan SNP genotyping kit was available for detecting the distribution of miR-146a rs2910164 genotypes. The kit information has been entered into the consumables list. The PCR total reaction volume was 10 µL, containing Master Mix 5 µL, typing probe primer mixture 0.5 µL, template DNA 10 ng, and RNase-free water. DNA amplification was carried out with the Roche LightCycler 480 II real-time fluorescence quantitative PCR instrument. Reaction conditions: Pre-denaturation at 95 °C for 10 min; 40 cycles (95 °C for 15 seconds, 60 °C for 1 min), and the FAM/VIC fluorescence was read at 60 °C. After the amplification was completed, the collected FAM/VIC dual fluorescence signals were analyzed using LightCycler 480 Software, and the genotype data were statistically processed. A single FAM signal represents a homozygous genotype, a single VIC signal represents another homozygous genotype, and the presence of both signals indicates a heterozygous genotype. Samples with abnormal signals or inconsistent results upon repetition will be re-tested. Each experiment was conducted with both template-free control and positive control for quality control. All samples were subjected to three technical replicates.
RT-qPCR
Total plasma miRNA extraction was performed from 100 µL plasma using a dedicated miRNA extraction kit. The kit information has been entered into the consumables list. The RNA concentration was determined using a spectrophotometer. The OD₂₆₀/OD₂₈₀ ratio of the extracted qualified miRNA samples ranged from 1.8 to 2.0. 200 ng of RNA was used for reverse transcription to synthesize cDNA, and the reaction procedure followed the standard instructions of the kit. Reverse transcription was performed in a total volume of 20 µL, including incubation at 42 °C for 60 min and inactivation at 85 °C for 5 min. The qPCR reaction was prepared following the established protocol, with a total volume of 20 µL. The reaction mixture was configured as follows: 10 µL of qPCR pre-mix, 0.4 µL of forward primer, 0.4 µL of reverse primer, 1 µL of cDNA template, and 8.2 µL of RNase-free water. The specific primers for miR-146a and the internal reference gene U6 were used. The amplification was completed using the Roche LightCycler 480 II real-time fluorescence quantitative PCR instrument. The qPCR thermal cycling conditions were: 95 °C for pre-denaturation for 30 s, followed by 40 cycles of denaturation at 95 °C for 5 s and annealing and extension at 60 °C for 30 s. All samples were subjected to three technical replicates. The experimental data were analyzed using the LightCycler 480 Software. Using U6 as the internal reference to correct the inter-sample variation, first calculate ΔCt (the Ct value of miR-146a - the Ct value of U6), then calculate ΔΔCt (the ΔCt of the experimental group - the ΔCt of the control group), and finally the relative expression level of miR-146a was obtained through 2⁻ΔΔCt.
ELISA
The serum levels of IgE, IL-4, IL-6, and IL-10 were detected by ELISA kits. The experimental procedures were referenced in the instruction manual. Specific steps were as follows: Firstly, the concentrated washing solution was diluted, and the standards were gradiently diluted to prepare working solutions for the standard curve. Secondly, the 50 µL diluent, standard solution, and the sample to be tested were added to the wells and incubated at 37 °C for 60 min. After incubation, the wells were washed three times with washing buffer. Subsequently, 50 µL of enzyme-conjugated antibody working solution was added, and the plates were incubated at 37 °C for 30 min. After the incubation was completed, the liquid was discarded, and the wells were washed again, followed by the addition of chromogenic solution for a 15-min incubation at 37 °C in the dark. After adding the stop solution, the absorbance was measured at 450 nm using a microplate reader. Sample concentrations were calculated according to the standard curve. Each sample was tested three times. Data with a coefficient of variation less than 10% were considered valid. Blank wells and control wells were set up during the experiment for quality control. The detection range and sensitivity of the kit complied with the regulations specified in the manufacturer's manual.
Data statistics
The experimental data were analyzed using SPSS and GraphPad Prism 9 softwares. The data were presented as mean ± standard deviation (mean ± SD). The Shapiro-Wilk test was used to assess the normality of continuous variables, and Levene’s test was applied to evaluate homogeneity of variance. Comparison of continuous variables between the two groups was analyzed using the independent samples t-test. One-way ANOVA followed by Tukey’s post-hoc test was performed for multiple group comparisons, and Two-way ANOVA was applied to evaluate the main effects of two independent factors and their interaction effect. Outliers were identified and excluded based on the 3-standard deviation rule. No missing data were detected in this study. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic efficacy of miR-146a for AR. Relevant ROC parameters and 95% confidence intervals were calculated using built-in statistical algorithms. Pearson correlation analysis was used to measure the linear correlation between miR-146a expression and the levels of serum-related factors. Univariate and multivariate logistic regression analyses were conducted to screen risk factors for AR. Variables with p < 0.05 in univariate analysis were included in the multivariate logistic regression model. p < 0.05 was considered statistically significant.